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Abstract
Background To evaluate the incidence of posterior vitreous
detachment (PVD) induced by intravitreal injection of
different intravitreal drugs.
Methods This prospective observational study included 61
patients (61 eyes) with different underlying retinal diseases:
exudative age-related macular degeneration (n=47), cystoid
macular edema (CME) after retinal vein occlusion (n=8),
and CME of other origin (n=6). Bevazicumab (1.25 mg)
was injected into 25 eyes, ranibizumab (0.5 mg) into 27
eyes, triamcinolone (4 mg) into six eyes, and a combination
of bevacizumab and triamcinolone into three eyes. Patients
with initial PVD were excluded. Patients were followed
for at least 4–6 weeks after their last injection by
Fourier-domain OCT, fundus biomicroscopy and ultra-
sound B-examination.
Results Overall, 15 of 61 eyes developed a PVD after intra-
vitreal injection (n=6 after ranibizumab, n=7 after bevaci-
zumab and n=2 after triamcinolon) within a mean follow-up
period of 11.1 weeks. PVD occurred in three eyes after the
first injection, in three eyes after the second, and in seven
eyes after the third injection. Incidence of PVD correlated
with increasing age.
Conclusion Intravitreal injection of commonly-used drugs
seems to induce posterior vitreous detachment, which may
thus influence the outcome of the underlying disease.
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Introduction
In the last decade, intravitreal injection has become the most
important drug-administration route in several retinal dis-
eases. Studies have shown that the vitreoretinal interface
plays a key role in the development of macular pathologies
[4, 6, 7, 11, 13, 15]. An attached posterior vitreous cortex is
associated with a higher incidence of diabetic macular ede-
ma [9], and macular edema has been seen to resolve after
spontaneous vitreous detachment. It is reported that surgical
posterior vitreous detachment (PVD) is able to reduce mac-
ular edema in diabetic maculopathies [5, 16], age-related
macular degeneration [8], and retinal vein occlusions [1].
Recent studies have proposed the potential negative influ-
ence of attached posterior vitreous hyaloid on the develop-
ment of exudative age-related macular degeneration [4, 11].
Thus, efforts were made to identify an intravitreal substance
capable of creating posterior vitreous detachment (PVD). A
phase II multicenter study demonstrated that microplasmin
can induce safe posterior vitreous detachment after intra-
vitreal injection in patients with vitreomacular traction
syndromes [14].
It is still unknown whether the intravitreal injection pro-
cedure itself using standard intravitreal drugs such as VEGF
inhibitors or triamcinolone induces a PVD, and whether
there is any correlation to the injected volume or drug. In
the control arm of the recently published phase III ocriplas-
min study, PVD could be observed by injecting 0.1 ml of a
sham-solution in 10.1 % of patients [18].
The aim of this prospective observational study was to
evaluate the incidence of posterior vitreous detachment after
intravitreal injections of currently-used intravitreal drugs.
Clinical trial registration As it was an observational study, there has
been no clinical trial registration.
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Material and methods
Inclusion criteria were an attached posterior vitreous
membrane and the indication of intravitreal injections
for macular disease.
Exclusion criteria were preexisting traction syndromes,
former vitrectomy or complicated cataract surgery, and
detectable posterior vitreous detachment.
Sixty-one eyes of 61 patients (32 female, 29 male) with
attached posterior hyaloid were included. Table 1 illustrates
the various underlying diseases. Indications for intravitreal
injections were exudative age-related macular degeneration
(n=47), macular edema caused by retinal vein occlusion
(n=8), diabetic macular edema (n=4), cystoid macular
edema after cataract surgery (n=1) and uveitis (n=1).
The patients’ mean age was 72 years (SD ± 10.25).
Demographic data are shown in Table 1. The mean
follow-up period was 11.1 weeks. Patients with a history
of former intravitreal injections and an attached vitreous (36
patients) were also included in the study, and the number of
former injections was recorded. As this circumstance might
have an effect on the study outcome, the patient group
without previous intravitreal injections and that of patients
with former intravitreal injections were evaluated separately.
Patients with a macular hole or an epiretinal membrane
were excluded from the study.
Examinations
Follow-up examinations were performed on the day of
the scheduled reinjection. End point of the study was
either at detection of posterior vitreous detachment, or
at the control visit after a series of injections, usually
after three injections (14 weeks), when no further injections
were necessary.
To detect whether posterior detachment was present or
not, fundus biomicroscopy, ultrasound B imaging and
spectral-domain optical coherence tomography (Cirrus-OCT,
Zeiss) were performed (Figs. 1 and 2).
Decision on whether posterior vitreous was attached or
not was based on the following criteria:
In fundus biomicroscopy, PVD was assumed only if the
Weiss ring was visible. If it was not visible, attached vitre-
ous was assumed, but the other methods were assessed as
well and judgement was based on all informations.
In ultrasound-B examination, PVD was assumed, when
the posterior vitreous hyaloid was visible and showed no
connection to the optic nerve head. In the other cases,
vitreous attachment was assumed. See also Fig. 1.
In OCT vitreous attachment was assumed:
– when there was slight or partial detachment visible on
the temporal or nasal edge of the scanning area, and the
vitreous was attached in the central and macular area,
– when there was foveal adhesion but partial detachment
temporally or nasally,
– when there was slight vitreous detachment between the
optic disc and the fovea,
– when there was no posterior vitreous hyaloid visible
at all (since it may be out of the antero/posterior
OCT range).
Posterior vitreous with OCT was only confirmed as de-
tached when the posterior vitreous hyloid was completely
identified with distance to the retinal/macular surface. Still
this could be a premacular lacuna, and information re-
garding the other methods (fundus biomicroscopy and
ultrasound B examination) were included in the decision
making.
As an accurate judgement of the posterior hyaloid can be
very difficult, we believe that by using a combination of
these methods we can guarantee the highest sensitivity and
specificity currently achievable. We based our decision on
the results of all three methods to achieve the highest spec-
ificity and sensitivity available. Patients in whom decision-
making on state of vitreoretinal interface at baseline was not
possible have not been included in the study.
Intravitreal drugs used in this study (see Table 2)
included bevacizumab (Avastin®) in 25 patients, ranibizumab
Table 1 Demographical data
Total number of patients (n) 61
Age (years) mean ± SD (min–max) 72±10.25 (36–95)
Gender Female 32
Male 29
Refraction (dpt.) mean ± SD (min–max) +1.29±2.0 (−3.75 to +8.75)
Lens status 12 pseudophakic eyes
49 non pseudophakic eyes
Diagnosis
Exudative age-related macular degeneration 47
Retinal vein occlusion 8
Macular edema of other regions 6
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(Lucentis®) in 27 patients, and triamcinolone in six patients.
Three patients received a combination of triamcinolone and
bevacizumab. The injected volume of VEGF-inhibitors was
0.05 ml and 0.1 ml of triamcinolone respectively.
Regression analysis was performed to evaluate a possible
influence of particular medication on the rate of induced
PVD.
The intravitreal injections were performed under aseptic
conditions according to the recommendations of the German
Ophthalmologic Society.
Statistical analysis
Statistical analysis was performed using the software
“Statistika” (Statistica software, StatSoft Inc., Tulsa, OK,
USA) and Fisher’s exact test.
Results
Fifteen of 61 patients (24 %) had a newly-diagnosed poste-
rior vitreous detachment during the observation period.
PVD was diagnosed after the first injection in 3/61 patients,
after the second injection in 3/58 patients, in 7/55 patients
after the third injection, and in 1/48 patients after injection 5
and 1/47 after injection 6 (see Fig. 3). Seven of these 15
patients developed PVD after the third injection (Fig. 3).
PVD occurred more often with increasing age (p=0.0075
comparing the 60–69 years age group and those aged 70–
79 years). As shown in Fig. 4, we observed only one PVD in
the patients aged between 60 and 69 years, but six in the
following decade, and eight in the age group from 80 to
95 years.
There was no statistical significance with regard to gen-
der, underlying disease, left or right eye, or injected drug.
No difference was observed with regard to the rate of PVD
development comparing the subgroups of patients who had
undergone intravitreal injections before entering the study,
and patients who had not had any intravitreal injections
before entering the study (see Fig. 4). The state of vitreo-
macular interface at baseline between these subgroups
showed no significant difference using the three examina-
tion methods.
The level of concordance between the results of PVD
seen by the three diagnostic methods was as follows: one
patient showed PVD in all methods, two patients showed
PVD in ultrasound B imaging only, two patients in OCT
examination only, and two patients in fundus biomicroscopy
only. Eight patients showed PVD in ultrasound B imaging
as well as in fundus biomicroscopy.
In our study, three of the 15 patients who developed PVD
were pseudophakic. There was no statistical significantly
higher rate of PVD in pseuphakic eyes.
Discussion
Intravitreal drug injection has become the most important
treatment of different macular diseases, and is widely used.
Progression of several macular diseases seems to be affected
by vitreous adhesion, and PVD may reduce macular edema
or exudative age-related macular degeneration [4, 6, 7, 11].
Fig. 1 US-B revealed. a No
PVD before injection. b PVD
after injection
Fig. 2 Cirrus-OCT. a Foveal
vitreous adhesion. b Posterior
hyaloid not visible/detectable
after VCD
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The purpose of our study was to discover whether intra-
vitreal injection induces posterior vitreous detachment, and any
correlation with the number of injections or drug used. Sixty-
one patients with attached posterior hyaloid were followed after
one or more intravitreal injections over an 11.1-week period
(mean) during which 15 eyes (24 %) presented a PVD.
A limitation of our study is the relatively small number of
enrolled patients and the lack of an age-matched control
group. Therefore, our study's PVD rate must be compared to
published data: regarding the prevalence of PVD, Weber-
Krause et al. published an overview of 703 patients from age
65 to >−90 years [15]. In those patients aged 65–69 years the
incidence of complete PVD (partial PVD) was 11 %(17 %),
between 70 and 79 years 35% (9%), between 80 and 89 years
46 % (11 %), and over 90 years 49 % (12 %) respectively.
Weber-Krause et al. reported a prevalence ranging from
27 % to 61 % in different age groups (60 to 90 years),
which corresponds to an incidence of 1.3–1.6 % per year.
However, they did not include patients with diabetic
macular edema or proliferative retinal diseases in their
study. Nevertheless, the high number of eyes developing
a posterior vitreous detachment within a relatively short
period after intravitreal injection in our study indicates
that rather than being coincidental, PVD is induced by
the intravitreal injection.
We observed a correlation between age and the incidence
of PVD, noting a significant increase in PVD (p=0.0075)
when comparing the age groups of patients under and over
70 years.
In the ocriplasmin study by Stalmans et al., 10.1 % of 188
patients in the control group, receiving a sham-injection of 0.1ml,
developed a PVD [18]. It remains speculative wshether more
injections may have created a higher rate of PVD in their study.
As stated in the literature, PVD is more likely to occur in
myopic patients at a younger age [12, 17]. Vitreous volume
and size of the eye might also play an important role on the
development of PVD after intravitreal injection. Refraction
error in our study seems to be insubstantial, as most of our
patients were hyperopic (mean of +1.3 dpt., SD ± 2.0 dpt,
range: from −3.75 to +8.75 dpt.).
Axial length measurement in future studies would be
helpful to figure out the influence of eye size on the rate
of developing a PVD after intravitreal injection. Different
injection volumes might also lead to a higher rate of PVD.
Interestingly, none of the patients treated in this study with a
combination of bevacizumab and triamcinolone developed a
PVD despite the higher volume.
Although regression analysis in our study could not
prove an influence on the development of a PVD regardless
which type of drug or volume was used, the small sample
size must be considered.
A further problem of the study is a mixture of different
underlying diseases, which might themselves have an influ-
ence on the development of a PVD. In our study, one patient
with CME after cataract surgery was included, and one patient
with uveitic macular edema. In these two cases we detected
PVD after injection. Inflammation or recent cataract extrac-
tion may promote a posterior vitreous detachment.
Another potential source of error is the posterior vitreous
assesment. As macular surgery experience has shown us, it
Table 2 Distribution of
intravitreal drugs administered Bevacizumab Ranibizumab Triamcinolone
Patients (n) 25 27 9
PVD (n) 7 6 2
Number of injections 3.0 3.17 2.5
Mean follow up period [weeks] 10.17 11.3 9.08
Fig 3 Correlation between occurence of PVD and number of
injections
Fig 4 Occurence of PVD showing a correlation with the age of
patients
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can be very hard to detect posterior vitreous detachment, and
several studies have revealed that different diagnostic methods
can deliver misleading data, with high variance in the reported
data. During biomicroscopy, lacunae in the vitreous may
simulate a PVD, although the posterior hyaloid remains at-
tached to the retina. Furthermore, extensive liquefaction is not
necessarily a sign of PVD [2, 10]. Ultrasound seems to be the
most reliable method for detecting PVD [15]. But as resolu-
tion is not very high, little or a partially-detached vitreous may
not be visible. The high resolution of spectral-domain OCT
delivers additional information on the vitreomacular interface
and detects even very slight detachments or adhesions near the
retina [3]. However, a completely attached vitreous may be
missed, as well as a highly-detached posterior hyaloid, float-
ing anterior to the OCT’s limited axial scan area.
Since all these methods have their pros and cons, we used
all three to provide the optimum available sensitivity at
which to evaluate the posterior vitreous cortex situation
correctly, and to minimize diagnostic errors.
Interesting is the fact that the 24 % of PVD induction
observed in this study resembles the rate achieved in a
phase-III multicenter trial using intravitreal microplasmin
in patients with vitreomacular traction syndroms (TG-MV-
007). However, that rate was achieved after just one injec-
tion, whereas a higher rate of up to 58 % was described after
three injections of microplasmin in a phase-II trial [14].
Our study suggests that the intravitreal injection itself
may induce a PVD in patients with macular diseases. Older
age seems to raise the incidence of PVD after intravitreal
injection. Furthermore, a potential influence of the induced
PVD on the underlying macular disease must be considered.
As suggested in the literature, PVD may be associated with
better regression of edema, fewer recurrences of CME, and
it may even influence the recourse of age-related macular
degeneration. To exactly determine this influence, more
studies adressing this important issue are needed.
Conclusion
Intravitreal injection of commonly-used intravitreal drugs
seems to induce posterior vitreous detachment, and may
thereby influence the outcome of the underlying disease.
Advanced age seems to be a predisposing factor.
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